Valuation: Scholar Rock Holding Corporation

Market Cap 5.05B 4.51B 4.17B 3.78B 7.07B 480B 7.18B 50.16B 19.86B 251B 18.96B 18.56B 792B P/E 2026 *
-12.6x
P/E 2027 * -15.7x
Enterprise Value 4.74B 4.23B 3.91B 3.54B 6.62B 450B 6.73B 47.02B 18.62B 236B 17.78B 17.4B 743B EV / Sales 2026 *
835x
EV / Sales 2027 * 32.8x
Free-Float
99.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Scholar Rock Holding Corporation

1 day-1.12%
1 week+3.98%
Current month-14.13%
1 month-14.65%
3 months-12.96%
6 months-10.74%
Current year-5.81%
1 week 39.28
Extreme 39.285
43.36
1 month 38.69
Extreme 38.69
49.98
Current year 38.69
Extreme 38.69
61.76
1 year 27.07
Extreme 27.07
61.76
3 years 6.76
Extreme 6.76
61.76
5 years 4.32
Extreme 4.325
61.76
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 26/04/2025
Director of Finance/CFO 62 26/04/2025
Chief Tech/Sci/R&D Officer 51 31/08/2022
Director TitleAgeSince
Chairman 59 30/06/2017
Director/Board Member 53 31/07/2014
Director/Board Member 78 30/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/26 Don

Chief Operating Officer

-48,034 0.0394%
21/09/26 Don

Chief Executive Officer

-36,652 0.0301%
01/07/26 Sell

Director

-2,544 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%+3.98%+39.79%+441.64% 5.05B
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average +0.14%+2.57%+47.25%+170.96% 38.82B
Weighted average by Cap. +0.37%+2.75%+45.94%+146.73%

Financials

2026 *2027 *
Net sales 5.67M 5.07M 4.68M 4.24M 7.94M 539M 8.07M 56.33M 22.3M 282M 21.3M 20.84M 890M 142M 127M 117M 106M 198M 13.45B 201M 1.41B 557M 7.05B 532M 520M 22.22B
Net income -427M -381M -352M -319M -597M -40.54B -607M -4.24B -1.68B -21.24B -1.6B -1.57B -66.96B -358M -320M -296M -268M -501M -34B -509M -3.56B -1.41B -17.82B -1.34B -1.32B -56.17B
Net Debt -316M -283M -261M -237M -443M -30.04B -450M -3.14B -1.24B -15.74B -1.19B -1.16B -49.62B -410M -366M -339M -307M -574M -38.96B -584M -4.07B -1.61B -20.41B -1.54B -1.51B -64.35B
Projected Income Statement - Annual - Scholar Rock Holding Corporation
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
23/10/26 US$41.49 -1.12% 1,207,039
22/10/26 US$41.96 -2.42% 1,133,556
21/10/26 US$43.00 +3.97% 4,600,583
20/10/26 US$41.36 +2.78% 1,614,193
19/10/26 US$40.24 +0.85% 1,480,193
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Scholar Rock Holding Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
41.49USD
Average target price
70.44USD
Spread / Average Target
+69.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Scholar Rock Holding Corporation
  1. Stock Market
  2. Stocks
  3. SRRK Stock